Screening Blood Donors for High Titre Antibody to Herpes Varicella-Zoster

Vox Sanguinis ◽  
1980 ◽  
Vol 39 (6) ◽  
pp. 335-338 ◽  
Author(s):  
Maria Héjjas ◽  
Rajas Salker ◽  
J.A.J. Barbara
Vox Sanguinis ◽  
1980 ◽  
Vol 39 (6) ◽  
pp. 335-338
Author(s):  
Maria Héjjas ◽  
Rajas Salker ◽  
J.A.J. Barbara

Vox Sanguinis ◽  
1990 ◽  
Vol 59 (2) ◽  
pp. 83-85
Author(s):  
C. McDonald ◽  
J.A.J. Barbara ◽  
A. Al-Izzi ◽  
M. Contreras

1986 ◽  
Vol 382 (2) ◽  
pp. 399-403 ◽  
Author(s):  
Sadao Shiosaka ◽  
Hiroshi Kiyama ◽  
Akio Wanaka ◽  
Tohyama Masaya

The Lancet ◽  
1968 ◽  
Vol 292 (7560) ◽  
pp. 129-133 ◽  
Author(s):  
G.W. Boyd ◽  
W.S. Peart

2020 ◽  
Vol 34 ◽  
pp. 205873842093461
Author(s):  
Zekun Li ◽  
Zhenping Chen ◽  
Xiaoling Cheng ◽  
Xinyi Wu ◽  
Gang Li ◽  
...  

The factor VIII (FVIII)-neutralizing antibody (inhibitor) seen in 25%–30% of patients with severe haemophilia A (SHA). Vaccination is a non-genetic risk factor of inhibitor development as ‘danger signal’ which may provide a pro-inflammatory microenvironment to increase FVIII immunogenicity. We reported a previously treated SHA patient postponed the first vaccination to 15-month age received diphtheria-pertussis-tetanus intramuscularly. At 18-month age, the patient received Hepatitis A intramuscularly and Varicella Zoster Virus subcutaneously with 2 weeks interval and FVIII infusion was given <24 h prior for each. Successive bleedings occurred 1 week later with inefficacy of FVIII replacement. High-titre inhibitor was tested at 117 exposure days. This case suggested that continuous vaccinations in close proximity to FVIII could induce inhibitor. The relationship between vaccination and FVIII immunogenicity still needs to be revealed by further study.


1998 ◽  
Vol 143 (6) ◽  
pp. 1163-1170 ◽  
Author(s):  
D. R. Harper ◽  
N. Mathieu ◽  
J. Mullarkey

1970 ◽  
Vol 68 (3) ◽  
pp. 411-416 ◽  
Author(s):  
A. H. Tomlinson ◽  
F. O. MacCallum

SUMMARYThe sera of 308 patients, not suffering from varicella or zoster infections, and the sera of 183 blood donors were examined for complement-fixing antibody to varicella-zoster virus. In both groups about 70% of sera from persons aged 11–40 years had antibody titres ≥ 1/4; the incidence was less in the age range 41–60 years and increased in later decades. Antibody titres of 1/16 or 1/32 were noticeably less frequent in those aged 41–60 years than in younger or older groups.It was concluded that an unchanging titre of 1/16 or 1/32 was of no diagnostic significance. The age distribution of antibody was consistent with the theory that zoster only occurs when antibody has declined.


Sign in / Sign up

Export Citation Format

Share Document